Loading...
Loading...
Satellos Bioscience Inc.
Satellos Bioscience Inc.. Spoken Alpha tracks MSLE's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks MSLE's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MSLE.
curl https://api.spokenalpha.com/v1/companies/MSLE| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.57 | $2.33 | +10.2% | -0.6% | -1.8% |
| Q4 FY2026 | $2.78 | $2.47 | +12.6% | -0.3% | +0.1% |
| Q3 FY2026 | $2.68 | $2.32 | +15.7% | +2.4% | -0.1% |
| Q2 FY2026 | $2.93 | $2.50 | +17.3% | +6.2% | +7.2% |
| Q1 FY2025 | $2.81 | $2.60 | +8.1% | -0.9% | -3.0% |
| Q4 FY2025 | $2.81 | $2.43 | +15.6% | +4.6% | +7.3% |
| Q3 FY2025 | $2.86 | $2.57 | +11.2% | -3.8% | -0.8% |
| Q2 FY2025 | $2.92 | $2.50 | +17.0% | +5.6% | +6.6% |
| Q1 FY2024 | $3.14 | $2.57 | +22.2% | +4.9% | +6.2% |
| Q4 FY2024 | $2.98 | $2.51 | +18.8% | -1.1% | -1.7% |